Vendor, Parsippany, NJ, part of Nighthawk Biosciences, Inc.
Elusys Therapeutics Inc.
UEI ELP1DCK8L191, CAGE 1WEK8
5 awards and $123,555,742 obligated between March 12, 2024 and July 7, 2026, 40% under full and open competition, against 2.0 offers on average where reported. 1 of the awards trace back to a SAM.gov solicitation on this site.
Sells to
Awarding agencies by dollars.
| Office of Assistant Secretary for Preparedness and Response | $123,555,742 |
Industries
NAICS on the awards, by dollars.
| Pharmaceutical Preparation ManufacturingNAICS 325412 | $124,337,123 |
| Professional, Scientific, and Technical ServicesNAICS 541711 | -$781,381 |
How it wins
Awards by competition, set-aside and type.
| Not Competed | 2 |
| Full and Open Competition | 2 |
| Full and Open Competition After Exclusion of Sources | 1 |
| Small Business Set Aside - Partial | 1 |
| Definitive Contract | 3 |
Hear when Elusys Therapeutics Inc. wins an award and when a contract it holds is about to end.Follow it
Contracts ending soon
None of Elusys Therapeutics Inc.'s contracts with a published end date ends in the next 19 months.
Competes with
Vendors selling pharmaceutical preparation manufacturing to Office of Assistant Secretary for Preparedness and Response, by dollars.
| Bavarian Nordic A/SKvistgard | $463,402,837 |
| Emergent Biosolutions Canada Inc.Winnipeg | $355,528,256 |
| Alvogen, Inc.Pine Brook, NJ | $284,780,686 |
| Phlow Corp.Richmond, VA | $204,760,551 |
| Fresenius Kabi, LLCLake Zurich, IL | $148,135,037 |
| Chartwell RX LLCCongers, NY | $143,890,653 |
Solicitations it won
SAM.gov opportunities whose award USAspending attributes to this vendor.
- Anthrax Antitoxin (monoclonal antibody)
Office of Assistant Secretary for Preparedness and Response, Aspr/Orm-Sns
JustificationNAICS 325412Anywhere in the US75A50324C00006Awarded to Elusys Therapeutics Inc.
Posted May 3, 2024
Awards
Every award in the window, by dollars obligated.
| Contract | Awarding office | Described as | Obligated |
|---|---|---|---|
| 75A50324C00006Definitive Contract, April 30, 2024, Not Competed, 1 offersSolicitation | Aspr/Orm-SnsOffice of Assistant Secretary for Preparedness and Response | Anthim (Obiltoxaximab)NAICS 325412, PSC 6505 | $124,523,123 |
| 75A50121C00073Definitive Contract, March 12, 2024, Not Competed, 1 offers | Aspr/Orm-SnsOffice of Assistant Secretary for Preparedness and Response | Manufacture and Delivery of Anthim (Obiltoxaximab)600mg/6ml Injection, an Anthrax Antitoxin CountermeasureNAICS 325412, PSC 6505 | -$86,000 |
| HHSO100201300010IApril 7, 2026, Full and Open Competition After Exclusion of Sources, 5 offers | Barda - Aspr / Daappo / Barda DCMAOffice of Assistant Secretary for Preparedness and Response | Manufacture and Delivery of Mab Anthrax Antitoxins - Modification P0007 Is to Deobligate the Remaining Funds and Close the Order.NAICS 325412, PSC AN13 | -$100,000 |
| HHSO100201100034CAugust 6, 2024, Full and Open Competition, 1 offers | Barda - Aspr / Daappo / Barda DCMAOffice of Assistant Secretary for Preparedness and Response | The Purpose of This Bilateral Modification Is to De-Obligate Canceling Funds from Requisition OS212728 of $282,172.97, Update Section F.2. DNAICS 541711, PSC C118 | -$282,173 |
| HHSO100201000026CDefinitive Contract, August 8, 2024, Full and Open Competition, 2 offers | Barda - Aspr / Daappo / Barda DCMAOffice of Assistant Secretary for Preparedness and Response | Elusys 0026C MOD#1 9 DE-OB Cancelling FundsNAICS 541711, PSC AN13 | -$499,208 |
- Places of performance
- New Jersey
- Product and service codes
- 6505 Drugs and BiologicalsC118 Arch-Eng Svcs - ConstructionAN13 Health R&D Services; Health Care Services; Experimental Development
- Transactions
- 12 across 5 awards